Efficacy of polatuzumab vedotin versus conventional chemotherapy in relapsed or refractory diffuse large B-cell lymphoma
Authors:
- 15 October 2025
- journal article
- research article
- Published by Springer Nature in International Journal of Hematology
- Vol. 123 (2) , 208-214
Abstract
Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) has a poor prognosis, particularly in patients ineligible for autologous stem cell transplantation or cellular immunotherapy. This study evaluated the effectiveness of polatuzumab vedotin combined with rituximab and bendamustine (PBR) therapy in comparison to conventional chemotherapy in patients with R/R DLBCL. Of 86 patients with first relapse or primary refractory DLBCL, 32 received PBR in any subsequent line, while 54 received conventional chemotherapy alone. For comparison, 32 baseline-matched patients were selected from these 54 and defined as the conventional chemotherapy group. The median overall survival (OS) for all patients was 17.3 months (range, 1.5–85.7 months), with the PBR-treated group showing significantly improved outcomes (median OS 19.7 vs. 15.8 months, P = 0.025). Univariate and multivariate analyses identified PBR as a favorable prognostic factor for OS. In the second-line setting, 41.2% of patients who received PBR were ≥ 80 years, compared with just 11.1% of those who received salvage regimens. Despite this older age distribution, the PBR group showed a trend toward favorable progression-free survival. These results suggest that PBR therapy is more effective and tolerable than conventional chemotherapy in patients with R/R DLBCL.Keywords
This publication has 37 references indexed in Scilit:
- Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing AnalysisClinical Lymphoma Myeloma and Leukemia, 2021
- Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experienceLeukemia & Lymphoma, 2020
- Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network reportBlood, 2020
- A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic ImplicationsCancer Cell, 2020
- Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell LymphomaJournal of Clinical Oncology, 2020
- Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomesNature Medicine, 2018
- Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 studyBlood, 2017
- The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood, 2016
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano ClassificationJournal of Clinical Oncology, 2014
- Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab EraJournal of Clinical Oncology, 2010